Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF – Get Free Report) saw a large drop in short interest during the month of July. As of July 15th, there was short interest totaling 696,739 shares, a drop of 70.6% from the June 30th total of 2,368,940 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞ days.
Shanghai Junshi Biosciences Stock Performance
Shares of OTCMKTS:SHJBF opened at C$3.35 on Friday. The company has a 50-day moving average price of C$3.35 and a two-hundred day moving average price of C$3.14. Shanghai Junshi Biosciences has a twelve month low of C$2.99 and a twelve month high of C$4.23.
Shanghai Junshi Biosciences Company Profile
Shanghai Junshi Biosciences Co, Ltd. is a Shanghai-based biopharmaceutical company dedicated to the research, development and commercialization of monoclonal antibody therapeutics. Since its founding in 2012 as a spin-off from the Shanghai Institute of Pharmaceutical Industry, Junshi has focused on leveraging cutting-edge antibody engineering platforms to develop innovative treatments for oncology, autoimmune conditions, infectious diseases and metabolic disorders. The company’s lead product, toripalimab (Tuoyi), was among the first anti-PD-1 antibodies approved by Chinese regulatory authorities for the treatment of advanced melanoma and nasopharyngeal carcinoma, demonstrating Junshi’s capability to translate research into commercially available immuno-oncology therapies.
Junshi’s pipeline encompasses a diversified portfolio of antibody-based candidates targeting immune checkpoints, cytokines and other disease-associated proteins.
See Also
- Five stocks we like better than Shanghai Junshi Biosciences
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for Shanghai Junshi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shanghai Junshi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
